The article examines why, even with €60 billion in state‑backed funding, new housing construction in Germany is lagging. While the housing minister pledges a new construction push, industry insiders point to deeper structural issues as the main cause of the slowdown.
The Euribor started the week with a new cut in its daily rate, leaving the monthly average at 3.271% in October, an increase of 0.024 points compared with the previous month, which is welcomed by mortgage borrowers.
The article features Rui Mota Guedes, General Director of Loreto Inversiones, answering questions about the most promising assets and sectors and the trends that will shape stock markets in the near future, with a focus on the outlook for 2027.
In a Bloomberg interview, EY Global Vice Chair Andrea Guerzoni discussed a decline in confidence among CEOs, with the EY-Parthenon survey showing the confidence index drop from 62% to 51%.
Vanguard issued a warning that France is facing a credit downgrade as its borrowing costs rise sharply, a situation worsened by the financial strain from the Iran war and looming budget negotiations in Paris.
The luxury hotel that once operated as the Hilton Frankfurt Gravenbruch is now insolvent. Its owner faces EU and US sanctions due to alleged ties with Iran, and the hotel’s fate now rests with governmental authorities.
Eycore, a Polish space startup, anticipates rapid revenue growth as European states race to acquire independent satellite intelligence capabilities.
Felix Pakleppa, the chief executive of the German Construction Industry Association (ZDB), argued that subsidies for new housing construction are not a cost but an investment, and that more reliable and stronger support for the sector would ultimately improve public finances.
ArcelorMittal announced it will close its Ukrainian plant in Kryvyi Rih following Russian attacks that killed workers, and expects to record a $1 billion impairment charge.
Despite plans to broaden its business beyond obesity treatments, the Danish group’s forecasts are modest, indicating limited growth prospects outside its weight‑loss medication portfolio.